Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04489797 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04489797 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 35 participants.
The verdict
NCT04489797, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.
Interventions
- DRUG Acalabrutinib
- DRUG Rabeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04489797
The ClinicalTrials.gov registry entry for NCT04489797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acalabrutinib is the first listed.
NCT04489797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04489797 about?
NCT04489797 is a clinical study titled "A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants". This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.
What is the current status of trial NCT04489797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-07-20. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT04489797?
The interventions under investigation include: Acalabrutinib (DRUG), Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT04489797?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.